These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29767407)

  • 1. The difficult business of assessing new therapies for smouldering multiple myeloma.
    Zonder JA
    Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
    Hughes D; Yong K; Ramasamy K; Stern S; Boyle E; Ashcroft J; Basheer F; Rabin N; Pratt G
    Br J Haematol; 2024 Apr; 204(4):1193-1206. PubMed ID: 38393718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T; Callander N
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Detection of Precursor Diseases of Multiple Myeloma.
    O'Donnell EK; Borden BA; Ghobrial IM
    Hematol Oncol Clin North Am; 2024 Aug; 38(4):743-753. PubMed ID: 38724285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burning questions about smouldering myeloma.
    DeWeerdt S
    Nature; 2020 Nov; 587(7835):S58-S59. PubMed ID: 33239807
    [No Abstract]   [Full Text] [Related]  

  • 7. Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question.
    Vaxman I; Gatt ME
    Br J Haematol; 2024 Apr; 204(4):1141-1142. PubMed ID: 38429858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoldering multiple myeloma current treatment algorithms.
    Rajkumar SV; Kumar S; Lonial S; Mateos MV
    Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
    Rajkumar SV; Bergsagel PL; Kumar S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The screening imperative for multiple myeloma.
    Rajkumar SV
    Nature; 2020 Nov; 587(7835):S63. PubMed ID: 33235369
    [No Abstract]   [Full Text] [Related]  

  • 14. Smoldering multiple myeloma: Reviewing the rationale for intervention.
    Gertz M
    Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
    Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
    Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
    [No Abstract]   [Full Text] [Related]  

  • 16. Physicians, paraproteins and progress: diagnosis and management of myeloma.
    Pawlyn C; Jackson GH
    Br J Hosp Med (Lond); 2019 Feb; 80(2):91-98. PubMed ID: 30746991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoldering multiple myeloma 40 years later: a story of unintended disease.
    Yavorkovsky LL
    Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
    [No Abstract]   [Full Text] [Related]  

  • 18. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults.
    Guerard EJ; Tuchman SA
    Clin Geriatr Med; 2016 Feb; 32(1):191-205. PubMed ID: 26614868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.